evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,476 questions · 1,535 findings · 101 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 233 · 15.2%GRADE not reported 332 · 21.6%Very low 209 · 13.6%Low 343 · 22.3%Moderate 279 · 18.2%High 139 · 9.1%

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Progression‐free survival · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Overall response rate Duration of · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall response rate Duration of compared with chemotherapy alone (low certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Adverse event (any) Duration of · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher adverse event (any) Duration of compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Severe adverse event (grade ≥ 3 ) Duration of · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

Overall response rate (ORR), · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (high dose interferon) plus chemotherapy changes overall response rate (ORR), measured after 8 weeks of treatment and… compared with neoadjuvant chemotherapy (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Progression‐free survival · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (high certainty).

1 finding from 1 review